Sugi Predict

Sugi Predict / Compounds / SCHEMBL21686844

SCHEMBL21686844

SCHEMBL21686844

Clc1cc2c(Cl)nc(Cl)nc2cn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 1/20 0.34
▸ GABRD O14764 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRB1 P18505 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ GABRB2 P47870 1/20 0.34
▸ GABRA4 P48169 1/20 0.34
▸ GABRE P78334 1/20 0.34
▸ GABRA6 Q16445 1/20 0.34
▸ GABRG1 Q8N1C3 1/20 0.34
▸ GABRG3 Q99928 1/20 0.34
▸ GABRQ Q9UN88 1/20 0.34
▸ EGFR P00533 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29870732 1.00 GABRP (0.34) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30593373 0.83 ALDH1A1 (0.32) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL22220609 0.83 ALDH1A1 (0.32) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31332420 0.80 CYP1A2 (0.35) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL30006942 0.80 HTT (0.36) ALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL24800367 0.80 ALDH1A1 (0.37) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL21687035 0.80 CYP1A2 (0.35) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL24342283 0.80 HTT (0.36) ALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL31693082 0.80 HTT (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30772171 0.80 ALDH1A1 (0.37) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025202022-A9 ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 BAYER AKTIENGESELLSCHAFT (DE) 2025-12-26 — — WO disclosed
US-12492199-B2 Pyridopyrimidines as histamine H4-receptor inhibitors FAES FARMA, S.A. (ES) 2025-12-09 — — US disclosed
WO-2025202022-A1 ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 BAYER AKTIENGESELLSCHAFT (DE) 2025-10-02 — — WO disclosed
US-20240425501-A1 NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS SATYARX PHARMA INNOVATIONS PVT LTD (IN) 2024-12-26 — — US disclosed
WO-2024155706-A1 TRICYCLIC COMPOUNDS ZENO MANAGEMENT, INC. (US) 2024-07-25 — — WO disclosed
CN-112739699-B Pyridopyrimidine compounds as histamine H4 receptor inhibitors 费斯制药股份有限公司 2023-11-28 — — CN disclosed
CN-117088898-A Condensed ring pyrimidine compound, preparation method, pharmaceutical composition and application thereof 中国药科大学 2023-11-21 — — CN disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
WO-2023116779-A1 DIALKYNE COMPOUND AND USE THEREOF 上海艾力斯医药科技股份有限公司 2023-06-29 — — WO disclosed
EP-3827005-B1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA SA (ES) 2022-08-17 — — EP disclosed
US-20220204498-A1 PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2022-06-30 — — US disclosed
US-20220204498-A1 PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2022-06-30 — — US disclosed
EP-3927433-A1 PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2021-12-29 — — EP disclosed
CN-113795307-A Pyridopyrimidinyl compounds and methods of use thereof 基因泰克公司 2021-12-14 — — CN disclosed
US-20210300922-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA, S.A. (ES) 2021-09-30 — — US disclosed
US-20210300922-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA, S.A. (ES) 2021-09-30 — — US disclosed
CN-112739699-A Pyridopyrimidine compounds as histamine H4 receptor inhibitors 费斯制药股份有限公司 2021-04-30 — — CN disclosed
CN-107245075-B 2,4, 6-trisubstituted pyrido [3,4-d ] pyrimidine compound and salt and application thereof 西安交通大学 2020-03-17 — — CN disclosed
WO-2020020939-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA, S.A. (ES) 2020-01-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300922-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS HRH4, HRH3, HRH2 GABRP 1651/4885GABRD 3668/4885GABRA1 1568/4885
US-20240425501-A1 NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS KRAS, NRAS, SOS1 GABRP 2471/4885GABRD 3132/4885GABRA1 2281/4885
US-20220204498-A1 PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE XBP1, HSPA5, ERN2 GABRP 3144/4885GABRD 3652/4885GABRA1 4216/4885
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF KRAS, NRAS, HRAS GABRP 4312/4885GABRD 3607/4885GABRA1 4281/4885
US-12492199-B2 Pyridopyrimidines as histamine H4-receptor inhibitors HRH4, HRH2, HRH3 GABRP 1207/4885GABRD 2847/4885GABRA1 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback